eli lilly glp-1 medications portfolio The FDA approved a new pill from on Wednesday. The drug, called Foundayo, is the second GLP-1 weight-loss pill. CBS News' Dr. LaPook has more on the new medication The Bioinformatics Behind Eli Lilly's

It is available to patients with a body mass index (BMI) of over 30 kg/m or individuals with a BMI of over 27 kg/m alongside at least one weight-related condition, such as type 2 diabetes, prediabetes, high cholesterol, or sleep apnea

However, they are typically recommended as part of a comprehensive weight management plan that includes a healthy diet and regular physical activity

Results of clinical research trials

ABSTRACT KEY FIGURE Highlights INTRODUCTION DISCOVERY OF GLP-1 AND DEVELOPMENT OF INCRETIN-BASED DRUGS GLP-1 AND IMPLICATIONS IN COGNITIVE SATIATION: HUMAN STUDIES HYPOTHALAMIC FUNCTIONS IN COGNITIVE FEED-FORWARD REGULATION HYPOTHALAMIC CONTROL OF GLP-1 ACTIONS ON SATIATION AND SATIETY: ANIMAL STUDIES ONGOING FUTURE STUDIES OF GLP-1R AGONISTS NOTES REFERENCES About this article ABSTRACT Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as blockbuster drugs for treating metabolic diseases